Mark Gavin Lotter
Director Ejecutivo en Nuance Pharma (Shanghai) Co., Ltd. .
Perfil
Mark Gavin Lotter is the founder of NovaMed Pharmaceuticals, Inc. (founded in 2005) and Nuance Pharma (Shanghai) Co., Ltd.
(founded in 2014).
At NovaMed Pharmaceuticals, he held the titles of President & Chief Executive Officer from 2006 to 2010.
At Nuance Pharma (Shanghai) Co., Ltd., he is currently the Chief Executive Officer.
Mr. Lotter's former jobs include Director & CEO-China Operations at SciClone Pharmaceuticals LLC from 2011 to 2012, Chief Executive Officer at Aspen Pharmacare Holdings Ltd., Vice President-Operations at AstraZeneca Pharmaceuticals LP, and Independent Non-Executive Director at China Health Group, Inc. from 2015 to 2019.
Mr. Lotter received his undergraduate degree from the University of Natal and his MBA from the University of South Africa.
Cargos activos de Mark Gavin Lotter
Empresas | Cargo | Inicio |
---|---|---|
Nuance Pharma (Shanghai) Co., Ltd.
Nuance Pharma (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology Nuance Pharma (Shanghai) Co., Ltd. is a Chinese innovation-focused biopharmaceutical company founded in 2014 by Yi Bo Shao and Mark Gavin Lotter. The company is based in Shanghai, China, and has subsidiaries in Germany and China. Nuance Pharma's mission is to address critical unmet medical needs in the Pacific region. The company has a differentiated combination of commercial stage and innovative pipeline assets across respiratory, pain management, emergency care, and iron deficiency anemia. Nuance Pharma deploys the dual wheel model that incubates a late clinical stage innovative portfolio while maintaining a self-sustainable commercial operation. The company has assembled a portfolio of promising clinical-stage drug candidates for respiratory, pain, and iron deficiency anemia. Nuance Pharma's world-class clinical and regulatory teams, visionary approach to business development, and integrated commercial platforms enable the company to continuously accelerate the access of innovative treatments to patients. | Director Ejecutivo | 12/08/2014 |
Antiguos cargos conocidos de Mark Gavin Lotter.
Empresas | Cargo | Fin |
---|---|---|
CHINA HEALTH GROUP INC. | Director/Miembro de la Junta | 20/06/2019 |
SCICLONE PHARMACEUTICALS, INC. | Director/Miembro de la Junta | 14/12/2012 |
NovaMed Pharmaceuticals, Inc.
NovaMed Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NovaMed Pharmaceuticals Inc. engages in pharmaceutical preparations. It manufactures and distributes healthcare and pharmaceutical products. The company was founded by Mark Lotter, Min Geng Xiao and Bo Shao on August 1, 2005 and is headquartered in Shanghai, China. | Fundador | 18/04/2011 |
ASPEN PHARMACARE HOLDINGS LIMITED | Director Ejecutivo | - |
AstraZeneca Pharmaceuticals LP
AstraZeneca Pharmaceuticals LP Pharmaceuticals: MajorHealth Technology AstraZeneca Pharmaceuticals LP develops, manufactures and markets prescription pharmaceutical drugs. It sells products related to gastrointestinal, cardiovascular, neuroscience, respiratory and oncology infections. The company was founded in 1953 and is headquartered in Wilmington, DE. | Director de Operaciones | - |
Formación de Mark Gavin Lotter.
University of South Africa | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
ASPEN PHARMACARE HOLDINGS LIMITED | Health Technology |
CHINA HEALTH GROUP INC. | Health Technology |
Empresas privadas | 5 |
---|---|
NovaMed Pharmaceuticals, Inc.
NovaMed Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NovaMed Pharmaceuticals Inc. engages in pharmaceutical preparations. It manufactures and distributes healthcare and pharmaceutical products. The company was founded by Mark Lotter, Min Geng Xiao and Bo Shao on August 1, 2005 and is headquartered in Shanghai, China. | Health Technology |
University of Natal | Consumer Services |
AstraZeneca Pharmaceuticals LP
AstraZeneca Pharmaceuticals LP Pharmaceuticals: MajorHealth Technology AstraZeneca Pharmaceuticals LP develops, manufactures and markets prescription pharmaceutical drugs. It sells products related to gastrointestinal, cardiovascular, neuroscience, respiratory and oncology infections. The company was founded in 1953 and is headquartered in Wilmington, DE. | Health Technology |
SciClone Pharmaceuticals LLC
SciClone Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology SciClone Pharmaceuticals LLC was engaged in the development of therapeutic treatment for oncology, infectious diseases, and cardiovascular disorders. It was also offering ZADAXIN for the treatment of hepatitis B, hepatitis C, certain cancers, and used as immune system enhancer, and DC Bead which is used for the novel treatment of liver cancer. The company was founded in 1990 and was headquartered in San Mateo, CA. | Health Technology |
Nuance Pharma (Shanghai) Co., Ltd.
Nuance Pharma (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology Nuance Pharma (Shanghai) Co., Ltd. is a Chinese innovation-focused biopharmaceutical company founded in 2014 by Yi Bo Shao and Mark Gavin Lotter. The company is based in Shanghai, China, and has subsidiaries in Germany and China. Nuance Pharma's mission is to address critical unmet medical needs in the Pacific region. The company has a differentiated combination of commercial stage and innovative pipeline assets across respiratory, pain management, emergency care, and iron deficiency anemia. Nuance Pharma deploys the dual wheel model that incubates a late clinical stage innovative portfolio while maintaining a self-sustainable commercial operation. The company has assembled a portfolio of promising clinical-stage drug candidates for respiratory, pain, and iron deficiency anemia. Nuance Pharma's world-class clinical and regulatory teams, visionary approach to business development, and integrated commercial platforms enable the company to continuously accelerate the access of innovative treatments to patients. | Health Technology |
- Bolsa de valores
- Insiders
- Mark Gavin Lotter